GD2 and GD3 synthase: novel drug targets for cancer therapy.
Academic Article
Overview
Research
Identity
Additional Document Info
Other
View All
Overview
abstract
Our recent study suggests that targeting GD3 synthase (also known as ST8SIA1)-the rate-limiting enzyme in biosynthesis of the breast cancer stem cell marker GD2-abrogates metastasis and depletes the cancer stem cell populations within a tumor, thus providing an effective therapeutic strategy against metastatic breast cancers.